• Enkam presents new results at the Society for Neur
• Commercial Partnership with STEMCELL Technologies
• ENKAM Pharmaceuticals Engages The Sage Group as Ad
• Lead Drug FGL Found To Prevent Impaired Cognition
• R&D Update, Publication & Conference Presentation
• CHDI selects ENKAM’s compounds for preclinical tes
• Presentation at BIO-Europe
• Attendance at Conferences
• Participation at Conference
• The ENKAM approach shows potential in treatment of
• Discovery of Novel Compound Classes
• Positive Preclinical Data - Traumatic Brain Injury
• Appointment of Executive Chairman
• New Promising Treatment of Alzheimer’s Disease
• EU 6FP Grants EUR9.7 million to European Research
• Glossary

ENKAM Pharmaceuticals Engages The Sage Group as Advisors on Global Strategic Partnering in Neuroscience and Cancer

_________________________________________________________________

Copenhagen, Denmark, April 26, 2009 – ENKAM Pharmaceuticals A/S, the privately held biopharmaceutical development company focused on cancer and central nervous system disorders, is pleased to announce that it has engaged The Sage Group (“Sage”), a leader in the provision of strategic and transactional consultancy services to US and European healthcare and life science companies, to advise on global strategic partnering opportunities in order to realise the Company’s potential value.

The Sage Group works with healthcare and life science firms, including their investors and shareholders, to realize value through M&A, licensing and strategic partnering activities. Sage utilises its specialist knowledge of the healthcare and life science sector to identify and create opportunities for its clients such as ENKAM.

ENKAM utilises a unique discovery approach that enables the design of active, synthetic peptides that mimic specific functions of larger proteins. ENKAM was established to develop and commercialize research in cell adhesion and protein interactions at University of Copenhagen, particularly related to the Neural Cell Adhesion Molecule (NCAM, also the cluster of differentiation CD56). This has focused on the role of NCAM in cognition, neuroprotection, stem cell differentiation, and tumor growth and metastasis.

NCAM is an emerging target with blockbuster potential for Alzheimer’s disease, Schizophrenia and mood disorders. The company owns a large peptide library of over 1,000 molecules.ENKAM’s portfolio includes 4 products in or approaching clinical development. FGL_L, ENKAM’s most advanced product, is targeted at Alzheimer’s disease, and has a unique pharmacological profile with the potential to modify the progression of the disease. The drug successfully completed a Phase I clinical study in 2005 and is the first compound in its class to enter the clinic. FGL_L is currently being prepared to enter Phase II clinical trials.The Company is looking to partner its lead product, FGL_L in advance of entering into Phase II trials.

Morten Albrechtsen MD, Chief Executive and a founder of ENKAM Pharmaceuticals, said: “ENKAM has established a strong niche and has valuable assets to offer a partner. We are delighted to gain access to strategic and transactional support from a seasoned group of business developers and strategic transactionalists in realising the value of ENKAM’s portfolio.”

Commenting on this announcement, Dr. Bill Mason, Executive Director of The Sage Group said: “We are excited to have the opportunity to work with ENKAM in exploiting their exciting technology and ultimately realising value for their shareholders. ENKAM has a unique approach which is well advanced in terms of targeting key diseases in neuroscience and oncology. We will work with ENKAM to identify and engage with leading global companies who can collaborate with them to develop their potential and take their unique portfolio of products to market.”